Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma
Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.
Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.
IMMU-132 is an anti—TROP-2 antibody-drug conjugate comprised of SN-38. Regarding safety, the agent is not as toxic compared with other antibody-drug conjugates, Tagawa explains. In a phase I/II study, grade 3 neutropenia was observed in patients who received IMMU-132, but grade 1/2 diarrhea was one of the most common adverse events.
Preliminary findings demonstrate a median progression-free survival of 8.1 months with 50% maturity, and a median overall survival of 10.8 months, with 79% of patients still alive.
